癌症女性辅助生殖技术后的结局:系统综述与荟萃分析
该系统综述与荟萃分析比较了有癌症病史与无癌症女性在辅助生殖技术(ART)后的结局,检索截至2021年6月,纳入42项研究。结果显示,有癌症病史女性胚胎移植的返回率、临床妊娠率和活产率均低于无癌症女性。
要点
- 有癌症病史女性胚胎移植返回率低于无癌症女性(OR 0.22;95%CI 0.07, 0.74)。
- 有癌症病史女性临床妊娠率低于无癌症女性(OR 0.51;95%CI 0.35, 0.73)。
- 有癌症病史女性活产率低于无癌症女性(OR 0.56;95%CI 0.38, 0.83)。
核心结论
- 与无癌症女性相比,有癌症病史女性平均胚胎移植返回率更低,ART后临床妊娠和活产的可能性更低。
研究设计与样本
- 系统综述与荟萃分析,比较有癌症病史与无癌症女性在控制性卵巢刺激(COS)后的ART结局。
- 检索PubMed、Embase和Scopus截至2021年6月的原创英文研究,最终纳入42项研究。
- 每项研究中癌症女性中位数为58例(四分位距IQR=159),无癌症女性中位数为114例(IQR=348)。
主要发现
- 有癌症病史女性胚胎移植返回率低于无癌症女性(OR 0.22;95%CI 0.07, 0.74;95%预测区间0.00, 64.98)。
- 有癌症病史女性临床妊娠可能性低于无癌症女性(OR 0.51;95%CI 0.35, 0.73;95%预测区间0.19, 1.35)。
- 有癌症病史女性活产可能性低于无癌症女性(OR 0.56;95%CI 0.38, 0.83;95%预测区间0.19, 1.69)。
- COS持续时间、促性腺激素剂量、周期取消、总卵母细胞数和成熟卵母细胞数方面观察到显著的研究间异质性。
- 雌二醇峰值和卵母细胞成熟百分比的漏斗图不对称。
局限性
- 11项研究缺乏对年龄组间差异的充分控制,可能存在明显混杂。
- 大多数结局观察到研究间异质性。
- 数据缺乏限制了评估癌症临床因素(如非乳腺癌、癌症分期和治疗)和ART周期特征(如新鲜与冷冻胚胎移植及妊娠载体使用)对结局影响的能力。
- 需要进一步检查生殖结局和研究间异质性来源,以改善癌症诊断后ART预期成功率的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the associations between a history of cancer and outcomes after ART? SUMMARY ANSWER: Compared to women without cancer, on average, women with cancer had a lower return for embryo transfer and a lower likelihood of clinical pregnancy and live birth after ART. WHAT IS KNOWN ALREADY: Small, single-institution studies have suggested that cancer and its treatment may negatively affect ART outcomes. STUDY DESIGN, SIZE, DURATION: We conducted a systematic review with meta-analysis of studies comparing ART outcomes between women with and without cancer. PubMed, Embase and Scopus were searched for original, English-language studies published up to June 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: Inclusion criteria required reporting of ART outcomes after controlled ovarian stimulation (COS) among women with a history of cancer compared to women without cancer who used ART for any indication. Outcomes of interest ranged from duration of COS to likelihood of live birth after embryo transfer. Random-effects meta-analysis was used to calculate mean differences and odds ratios (ORs) with 95% CIs and 95% prediction intervals (PIs). We assessed heterogeneity by age-adjustment, referent group indication for ART, study location and among women with breast cancer and women who initiated ART before cancer treatment. We used visual inspection, Egger's test and the trim-and-fill method to assess funnel plot asymmetry. MAIN RESULTS AND THE ROLE OF CHANCE: Of 6094 unique records identified, 42 studies met inclusion criteria, representing a median per study of 58 women with cancer (interquartile range (IQR) = 159) and 114 women without cancer (IQR = 348). Compared to women without cancer, on average, women with cancer had a lower return for embryo transfer (OR: 0.22; 95% CI: 0.07, 0.74; 95% PI: 0.00, 64.98); lower likelihood of clinical pregnancy (OR: 0.51; 95% CI: 0.35, 0.73; 95% PI: 0.19, 1.35); and lower likelihood of live birth (OR: 0.56; 95% CI: 0.38, 0.83; 95% PI: 0.19, 1.69). Substantial among-study heterogeneity was observed for COS duration, gonadotropin dose, cycle cancellation, total oocytes and mature oocytes. Fertilization percentage showed less heterogeneity, but study-specific estimates were imprecise. Similarly, number of embryos showed less heterogeneity, and most studies estimated minimal differences by cancer history. Funnel plot asymmetry was observed for estradiol peak and oocyte maturation percentage. LIMITATIONS, REASONS FOR CAUTION: Appreciable confounding is possible in 11 studies that lacked adequate control for group differences in age, and among-study heterogeneity was observed for most outcomes. Lack of data limited our ability to assess how cancer clinical factors (e.g. cancers other than breast, cancer stage and treatment) and ART cycle characteristics (e.g. fresh versus frozen embryo transfers and use of gestational carriers) may affect outcomes. WIDER IMPLICATIONS OF THE FINDINGS: Women with cancer may be less likely to achieve pregnancy and live birth after embryo transfer. Further examination of reproductive outcomes and sources of heterogeneity among studies is warranted to improve evidence of the expected success of ART after a cancer diagnosis. STUDY FUNDING/COMPETING INTEREST(S): This research was supported in part by R01 CA211093 and P30 ES010126. C.M. was supported by the University of North Carolina Lineberger Cancer Control Education Program (T32 CA057726) and the National Cancer Institute (F31 CA260787). J.A.R.-H. was supported by the National Cancer Institute (K08 CA234333, P30 CA016672). J.A.R.-H. reports receiving consulting fees from Schlesinger Group and Guidepoint. The remaining authors declare no competing interests. REGISTRATION NUMBER: N/A.
引用
- Meernik C, Poole C, Engel SM, et al. Outcomes after assisted reproductive technology in women with cancer: a systematic review and meta-analysis. Hum Reprod. 2023. PMID: 36342891. doi:10.1093/humrep/deac235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。